entolimod

DRUG4 trials

Sponsors

Roswell Park Cancer Institute, Baylor College of Medicine, Robert J. Pignolo

Conditions

HealthyMucositisRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Early Phase 1

Entolimod, an Adjuvant for Vaccine Augmentation

CompletedNCT03063736

Baylor College of MedicineSubstance Use Disorders

Start: 2017-12-08End: 2019-12-31Updated: 2020-09-01

Phase 1

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

CompletedNCT01527136

Roswell Park Cancer InstituteUnspecified Adult Solid Tumor, Protocol Specific

Start: 2012-01-31End: 2014-10-31Updated: 2022-07-22

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

WithdrawnNCT01728480

Roswell Park Cancer InstituteMucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx +35

Start: 2014-01-31Updated: 2013-12-11

Phase 2

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

CompletedNCT04176133

Robert J. PignoloHealthy

Start: 2019-10-30End: 2022-03-30Updated: 2023-06-22